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Abstract
Background: Safety of live vaccines in patients treated with immunosuppressive therapies is not well known,
resulting in contradictory vaccination recommendations. We describe here the first case of vaccine-associated
measles in a patient on natalizumab treatment.
Case presentation: A young female patient with relapsing-remitting multiple sclerosis on natalizumab treatment
received the live attenuated measles, mumps, and rubella vaccine in preparation for a change in her treatment in
favour of fingolimod, with established immunosuppressive qualities. Seven days after receiving the vaccine, our
patient experienced diffuse muscle pain, fatigue, and thereafter developed a fever and then an erythematous
maculopapular rash, compatible with vaccine associated measles. This was later confirmed by a positive measles RT-
PCR throat swab. The patient’s symptoms resolved without any sequelae.
Conclusion: In this case report we review the immunosuppressive qualities of natalizumab and the evidence in
favour and against live vaccines in patients on this treatment. Our findings reveal the insufficient understanding of
the immunosuppressive effects of new immunomodulators, and thus of the safety of live vaccines in patients on
such medications. While this case triggers precaution, there is insufficient evidence to conclude that natalizumab
treatment could favor the onset of vaccine-associated measles.
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Background
Live-attenuated vaccines, including the Measles-Mumps-
Rubella (MMR) vaccine, consist of an attenuated micro-
organism still capable of replicating. They are generally
contraindicated in patients with immunosuppressive
therapies, by fear of systemic infection due to vaccine
strain replication [1]. Paradoxically, those patients are
more vulnerable to infectious diseases and would par-
ticularly benefit from immunization. Emergence of in-
creasingly diverse immunosuppressive treatments, whose
immunologic effect is not always clear, challenges this
general contraindication. At present, little data exists on
the safety of live-attenuated vaccines in those patients,
and recommendations are based on expert opinion that
may differ [2–6].
We describe here the first known case of vaccine-
associated measles in a young female vaccine recipient
with relapsing-remitting multiple sclerosis (RRMS),
treated with natalizumab. Our aim is to explore the
safety of vaccination in patients with multiple sclerosis
(MS), the immunosuppressive qualities of natalizumab
and the evidence in favour and against live vaccines in
patients on this treatment.
Case presentation
A 35-year-old patient with RRMS treated with natalizu-
mab injections for the past 3 years wanted to switch to
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an oral medication for practical reasons. She was there-
fore referred to our vaccination clinic in order to update
her vaccinations before switching to fingolimod, an oral
RRMS treatment with established immunosuppressive
properties. Given a lack of immunity to measles (IgG
negative), she was given the MMR vaccine following the
local recommendations that do not contraindicate live
attenuated vaccines in patients treated with natalizumab
[2]. She was also immunized with the hepatitis A, influ-
enza, diphtheria, tetanus, pertussis and pneumococcal
13-valent vaccines. Seven days post vaccination, she
started to experience diffuse muscle pain and fatigue. At
day 9 post vaccination, she developed a fever (38.5–
39 °C), and 2 days later she complained of a sore throat
and an erythematous maculopapular rash that spread
initially from the trunk and face, to the extremities. She
did not experience coryza, conjunctivitis or respiratory
symptoms. No travel history was reported, nor infectious
exposures. At day six of symptoms, she consulted a gen-
eral medicine outpatient clinic. The physical exam re-
vealed an erythematous maculopapular rash, posterior
right cervical and submandibular lymph nodes, and
slightly inflamed tonsils. No strawberry tongue or Koplik
spots were noted. Blood exams found a slightly elevated
C-reactive protein at 47 mg/dL, and normal white blood
cell count (6G/L). A rapid streptococcus throat test was
positive, which led the clinician to suspect either acute
streptococcal pharyngitis with scarlet fever or vaccine-
associated measles. Amoxicillin 500 mg twice daily was
prescribed for six days. Two days after the start of anti-
biotics, her fever broke and she described an improve-
ment in all of her symptoms. Eight days after the start of
the antibiotics, when she sought medical attention in
our vaccination clinic, she was asymptomatic, and her
physical examination was unremarkable other than her
fading rash without any desquamation. A measles RT-
PCR throat swab was performed at that time and the re-
sult came back positive at 1100 copies/ml. Other com-
mon respiratory viruses (influenza, respiratory syncytial
virus) were negative. Typisation of the measles strain
was not possible due to the small quantity of RNA.
Without the typisation of the measles strain, we
cannot ascertain that this was truly a case of vaccine-
associated measles. Indeed, wild type measles could
not be excluded, however the patient did not report
any contact with cases of measles or any sick contact.
The differential diagnosis of scarlet fever, another
viral febrile rash, or simply vaccine side-effects was
also considered. Nevertheless, the timeline of the vac-
cination and symptoms correspond typically with a
case of vaccine-associated measles. Given this high
probability, no formal contact tracing was conducted
by Public Health authorities and no secondary cases
were reported.
Upon communicating the results of the measles throat
swab and our diagnostic assessment, the patient was ini-
tially concerned about long lasting repercussions despite
being asymptomatic. Following a brief discussion, these
concerns were allayed.
Discussion and conclusions
This is the first case of a vaccine-associated measles in a
patient treated with natalizumab, based on a structured
search of PubMed, the Vaccine Adverse Event Reporting
System and VigiBase, the WHO global database of indi-
vidual case safety reports (ICSRs).
Measles vaccination has come back in the spotlight in
Europe and in the United States with a sharp resurgence
of measles cases since 2018, including in countries that
had previously interrupted endemic transmission [7, 8].
The measles vaccine is very effective, with on average
95.7% protection following the first vaccination [9].
While mild side effects are common (fever, transient
rash and transient lymphadenopathy in about 15, 5 and
20% of recipients, respectively), serious adverse effects
are rare (febrile seizures − 1 case per 3′000 doses-,
thrombocytopenic purpura − 1 case per 40′000 doses-,
and anaphylaxis – 1.8 to 14.4 cases per million doses)
[10]. Only a few cases of vaccine-associated measles have
been reported, both in immunocompetent [11, 12] and
immunocompromised [13–15] patients (real number of
cases probably higher due to underreporting).
Altogether, these risks are clearly inferior to those ob-
served with a natural measles infection [16].
While benefit of measles vaccination appears indisput-
able in healthy individuals, several aspects challenge the
risk-benefit ratio of measles immunization in the patient
described above, with MS treated with natalizumab.
Prevention of infection by vaccination is indeed an in-
tegral part of the management of patients with MS. [17]
Systemic infections have been shown to worsen clinical
symptoms of MS (pseudo-exacerbations) and may in-
crease the risk of MS relapse [18]. While there were
once concerns about vaccine safety in patients with MS,
two systematic reviews found no evidence of an associ-
ation between the most common vaccinations (including
the MMR vaccine) and the onset of MS. [19, 20] Fur-
thermore, no association was found between the risk of
MS relapse and influenza, H1N1, Hepatitis B and tet-
anus vaccines. However, evidence is lacking in regards to
the MMR vaccine [19].
The effect of natalizumab on vaccine tolerance may
also be questioned. Natalizumab is an immunosuppres-
sive treatment approved since 2004 for RRMS and ad-
ministered monthly by intravenous infusion. Over
200'000 people have been treated with natalizumab
worldwide [21]. It is a recombinant humanized mono-
clonal antibody that inhibits the α4-integrin subunit on
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leukocytes that has shown great clinical efficacy [22–24].
By blocking these cell-surface receptors, it reduces leu-
kocytes ability to adhere on brain endothelium and thus
to cross the blood-brain barrier [25]. Patients treated
with natalizumab present an inverted CD4+/CD8+ ratio
in cerebrospinal fluid, a finding often associated with
central nervous system (CNS) immunosuppression and
opportunistic infections [26]. Indeed, natalizumab has
been associated with a higher risk of progressive multi-
focal leukoencephalopathy, a CNS opportunistic infec-
tion caused by reactivation of a latent human
polyomavirus 2 (formerly JC virus) [27], and possibly
CNS herpesvirus infection [28]. While CNS immunosup-
pression by natalizumab treatment is well established,
the extent of its non-CNS immunosuppression remains
to be demonstrated. In fact, even if a decrease of IgG
and IgM levels in the blood of patients on natalizumab
treatment has been reported [29], clinical studies have
not found significantly higher incidences of non-CNS in-
fections compared to placebo groups and general popu-
lation cohorts [22, 30].
Nevertheless, while safety of inactivated vaccines (in-
fluenza, hepatitis B, human papillomavirus, tetanus vac-
cines) has been well established in patients treated with
natalizumab [31], data is scarce when it comes to live at-
tenuated vaccine tolerance, such as the MMR vaccine.
This has led international guidelines to advise against
the administration of the MMR vaccine in all patients
treated with immunosuppressive therapies including the
new biotherapies for MS due to fears of vaccine-
associated disease [5, 6, 31]. More specifically, French [4]
and Canadian [3] recommendations argue that despite
no supporting data, patients treated by natalizumab
should be considered as immunocompromised and thus
not be vaccinated with MMR. Yet a retrospective study
of 116 patients on immunosuppressive therapy (includ-
ing one patient on natalizumab treatment) matched with
a healthy control group found no difference in local and
systemic reactions after receiving a live attenuated vac-
cine [32]. Moreover, several other studies did not find
any worrying adverse effects after MMR vaccination in
patients with autoimmune diseases treated by metho-
trexate and/or biological agents [33] nor in patients on
immunosuppressive therapy after solid organ transplant-
ation [34]. These results and the lack of evidence of a
non-CNS immunosuppressive effect of natalizumab have
led Swiss experts to state that live attenuated vaccines
could be given to patients under such treatment after
careful risk/benefit ratio assessment [2].
There is insufficient evidence to conclude that natali-
zumab treatment could favor the onset of vaccine-
associated measles, as this case is isolated and vaccine-
associated measles have also been described in immuno-
competent patients. Nevertheless, this case calls for
caution when using live attenuated vaccines in patients
treated with immunosuppressive drugs, even without
theoretical or proven systemic immunosuppressive ef-
fect. This must of course be balanced with the risk of ac-
quiring wild-type measles, all the more in these
vulnerable patients. Finally, this case demonstrates the
importance of updating vaccinations before starting any
immunosuppressive therapy, and strengthening popula-
tion wide vaccination coverage to improve herd protec-
tion for the increasing number of patients on
immunomodulatory and immunosuppressive drugs.
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